Fortunes may be made in legal cannabis over the coming years. As a result, bullish sentiment is building on cannabis stocks both for recreational and medicinal uses.

Adding to the bullish sentiment is the first-ever cannabis-based medicine to get a favorable recommendation from an advisory panel to the U.S. Food and Drug Administration. This is a big win for cannabis.

The drug, a syrup called Epidiolex, is from GW Pharmaceuticals GWPH, +2.18% to treat childhood epilepsy. The medicine doesn’t have any psychoactive effects.

Let’s explore this Cambridge, England-based company with a chart, the fundamentals and then I’ll review other cannabis stocks. GW Pharmaceuticals, founded by two doctors, trades on the Nasdaq Stock Market in the U.S. GWPH, +2.18%


Please click here for the annotated chart of GW Pharmaceuticals stock. Please note the following from the chart:

• The stock recently moved up in anticipation of a favorable recommendation by the FDA panel.

• The stock price is now in the resistance zone shown on the chart.

• The move is on heavy volume.

• The relative strength index (RSI) shows that there is room to run.



This epilepsy drug has potential to generate over $1 billion in sales by 2022. The drug is derived from cannabidiol, or CBD. CBD has many medicinal properties that help a variety of conditions. The drug contains less than 0.1% tetrahydrocannabinol, or THC, which has mind-altering effects.

The company also has a pipeline of other promising cannabis-based drugs.

Buyout target

In our analysis at The Arora Report, GW Pharmaceuticals is a buyout target. To date, 134 of The Arora Report portfolio companies have been bought out. Buyouts produce great profits for investors, as suitors offer premiums to their share prices to get stockholders’ approval….Read more at MarketWatch.


A knowledgeable investor would have turned $100,000 into over $1,000,000 with the help from The Arora Report. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES, TAKE A FREE TRIAL TO PAID SERVICES.

Please click here to take advantage of a FREE  30 day trial.

Check out our enviable performance in both bull and bear markets.